MEI Pharma (MEIP) Receiving Somewhat Favorable Media Coverage, Report Finds
Media headlines about MEI Pharma (NASDAQ:MEIP) have trended somewhat positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. MEI Pharma earned a media sentiment score of 0.15 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.0078636526133 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
MEI Pharma (MEIP) opened at $2.12 on Friday. MEI Pharma has a fifty-two week low of $1.34 and a fifty-two week high of $3.26.
Several equities analysts have recently issued reports on MEIP shares. Zacks Investment Research cut MEI Pharma from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 8th. Oppenheimer reissued a “buy” rating and issued a $6.50 price objective on shares of MEI Pharma in a report on Monday. Cann reissued a “buy” rating and issued a $6.50 price objective on shares of MEI Pharma in a report on Monday. Finally, ValuEngine cut MEI Pharma from a “hold” rating to a “sell” rating in a report on Friday, December 1st.
TRADEMARK VIOLATION NOTICE: “MEI Pharma (MEIP) Receiving Somewhat Favorable Media Coverage, Report Finds” was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another site, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this news story can be viewed at https://www.watchlistnews.com/mei-pharma-meip-receiving-somewhat-favorable-media-coverage-report-finds/1765548.html.
MEI Pharma Company Profile
MEI Pharma, Inc is an oncology company. The Company is focused on the clinical development of drugs and therapies for treatment of cancer. The Company’s portfolio of clinical drug candidates includes Pracinostat, ME-344 and PWT143. Pracinostat is an orally available histone deacetylase (HDAC) inhibitor indicated for the treatment of advanced hematologic diseases, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
Receive News & Ratings for MEI Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEI Pharma and related companies with MarketBeat.com's FREE daily email newsletter.